<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096041</url>
  </required_header>
  <id_info>
    <org_study_id>TRIPLE-A</org_study_id>
    <nct_id>NCT03096041</nct_id>
  </id_info>
  <brief_title>Phase 3 Study Randomized Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors</brief_title>
  <acronym>TRIPLE-A</acronym>
  <official_title>Phase 3 Study Randomized Against Placebo, Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors in Adjuvant Treatment of Breast Cancer (TRIPLE-A)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Auriculotherapy is a complementary medicine, with few side effects, without contraindication,
      inexpensive and not very restrictive.Its efficacy has been found in several tests especially
      for the treatment of intraoperative pain. It remains more controversial in other indications.
      Evaluation of the value of auriculotherapy is often difficult because of the methodological
      limitations of the trials conducted. In the daily practice, the auriculotherapy is proposed
      to improve the articular pains of patients treated by AA. This Phase III study aims at
      validate this approach.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in the overall pain score</measure>
    <time_frame>3 months after auriculotherapy initiation</time_frame>
    <description>The proportion of patients with a 2-point or greater decrease in the overall pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Musculoskeletal Pain</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Auriculotherapy for analgesic use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controle arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo auriculotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auriculotherapy for analgesic use</intervention_name>
    <description>The ASP will be applied to specific pain points</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo auriculotherapy</intervention_name>
    <description>The ASP will be applied to placebo points (not specific to pain)</description>
    <arm_group_label>Controle arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years of age

          -  Patients with anti-aromatases in adjuvant treatment of breast cancer

          -  Menopausal women

          -  Treatment with aromatase inhibitors (anti-aromatase, AA) initiated for more than 3
             months. In the case of a change in anti-aromatase, the last treatment must be started
             for more than 3 months.

          -  Musculoskeletal pain appearing or increased under AA:

          -  Overall pain score of QCD ≥3 (on a scale of 0 to 10)

          -  Pain on at least 2 sites

          -  Pain for at least 3 months

          -  History of radiotherapy and / or adjuvant chemotherapy authorized

          -  Patients may have received tamoxifen

          -  Patient affiliated to a social security system

          -  Patient mastering the French language and able to complete the evaluation
             questionnaires

          -  Free and Informed Consent

        Exclusion Criteria:

          -  Patients who have already undergone treatment in auriculotherapy for the same
             indication

          -  Patient benefiting at the same time from a PNCAVT (acupuncture or homeopathy) for
             musculoskeletal pain

          -  Wearing hearing aids hindering the placement of semi-permanent needles (ASP)

          -  Wearing of a valve prosthesis

          -  Patient under guardianship or unable to give informed consent

          -  Patient unable to undergo medical follow-up for geographical, social or
             psychopathological reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie LELOUP-MORIT, MD</last_name>
      <phone>0231455050</phone>
      <email>v.leloupmorit@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Virginie LELOUP-MORIT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Paul d'Egine</name>
      <address>
        <city>Champigny sur Marne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freddy KAYEMBE, MD</last_name>
      <phone>01 49 83 67 21</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cognac-Jay - Forcilles</name>
      <address>
        <city>Férolles-Attilly</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David GUIGOU, MD</last_name>
      <email>dguigou@cognacq-jay.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique BASTIN, MD</last_name>
      <phone>0476765213</phone>
      <email>vbastin@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique BASTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris St Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel STAUDACHER, MD</last_name>
      <phone>0144127147</phone>
      <email>lstaudacher@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel STAUDACHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IGR</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine PAILLER, MD</last_name>
      <email>christine.pailler@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>auriculotherapy</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>adjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

